Prevencio Enters Canadian Market Through Strategic Partnership with Heart Fit Clinic
KIRKLAND, WA, UNITED STATES, July 22, 2025
EINPresswire.com/ — Prevencio, Inc., a pioneer in AI-powered cardiovascular diagnostics, today announced a strategic partnership with Heart Fit Clinic, Canada’s foremost network of preventive cardiology centers. This collaboration marks Prevencio’s first commercial expansion outside the United States—generating early international revenue and validating global demand for its next-generation cardiac blood tests.
Under the partnership, Heart Fit Clinic will offer Prevencio’s flagship tests:
• HART CADhs® – Diagnoses obstructive coronary artery disease
• HART CVE® – Predicts a patient’s one-year risk of heart attack, stroke, or cardiac death
Both tests have been rigorously validated across multinational clinical studies and are supported by more than 20 peer-reviewed publications. Most notably, HART CADhs recently received Breakthrough Device Designation from the U.S. FDA, highlighting its differentiated clinical utility and regulatory momentum.
